AVEO Pharmaceuticals Inc. (AVEO)

2.01
0.05 2.40
NASDAQ : Health Technology
Prev Close 2.06
Open 2.08
Day Low/High 2.01 / 2.10
52 Wk Low/High 1.49 / 3.59
Volume 311.46K
Avg Volume 2.82M
Exchange NASDAQ
Shares Outstanding 125.35M
Market Cap 254.45M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
AVEO To Present At The 28th Annual ROTH Conference

AVEO To Present At The 28th Annual ROTH Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 28th Annual ROTH Conference on Wednesday, March 16, 2016, at 9:00 a.

EUSA Pharma And AVEO Announce Submission Of Marketing Authorization Application For Tivozanib In Advanced Renal Cell Carcinoma

EUSA Pharma And AVEO Announce Submission Of Marketing Authorization Application For Tivozanib In Advanced Renal Cell Carcinoma

EUSA Pharma, a newly-established specialty pharmaceutical business, and AVEO Oncology (NASDAQ:AVEO) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for...

AVEO Announces Acceptance Of Registration Dossier For Tivozanib In RCC By The Ministry Of Health Of The Russian Federation

AVEO Announces Acceptance Of Registration Dossier For Tivozanib In RCC By The Ministry Of Health Of The Russian Federation

AVEO Oncology (NASDAQ:AVEO) today announced that a registration dossier seeking to obtain marketing authorization of tivozanib as a first line treatment of advanced renal cell carcinoma ("RCC") has been accepted by the...

AVEO To Present At The 18th Annual BIO CEO & Investor Conference

AVEO To Present At The 18th Annual BIO CEO & Investor Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016, at 9:00 a.

AVEO To Present At Biotech Showcase 2016

AVEO To Present At Biotech Showcase 2016

AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at Biotech Showcase 2016 on Wednesday, January 13, 2016 at 4:00 PM (PT) at the Parc 55 Wyndham in San...

AVEO Pharmaceuticals (AVEO) Stock Pops on European Licensing Agreement

AVEO Pharmaceuticals (AVEO) Stock Pops on European Licensing Agreement

AVEO Pharmaceuticals (AVEO) stock is surging in mid-morning trading on Monday after the company said it secured a licensing agreement for its renal cell carcinoma treatment in Europe.

AVEO And EUSA Pharma Announce Exclusive Licensing Agreement For Tivozanib In Europe

AVEO And EUSA Pharma Announce Exclusive Licensing Agreement For Tivozanib In Europe

AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma, a newly-established specialty pharmaceutical business with global reach, today announced an exclusive license agreement in which AVEO has granted EUSA Pharma European rights to...

AVEO Oncology Reports Third Quarter 2015 Financial Results And Provides Business Update

AVEO Oncology Reports Third Quarter 2015 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2015 and provided a business update.

AVEO Announces Chairman Tuan Ha-Ngoc Steps Down

AVEO Announces Chairman Tuan Ha-Ngoc Steps Down

AVEO Oncology (NASDAQ:AVEO) today announced that Tuan Ha-Ngoc, after 13 years of service and leadership at AVEO, has stepped down as Chairman and a Director of the Company's board of directors, effective November 6, 2015,...

When Eyeing Small Biotechs, Partnerships Are Huge

When Eyeing Small Biotechs, Partnerships Are Huge

Key collaboration deals with deeper-pocketed concerns can improve the odds of investment success.

AVEO Announces Exclusive Worldwide License Agreement For The Development And Commercialization Of AV-380 And Related Antibodies

AVEO Announces Exclusive Worldwide License Agreement For The Development And Commercialization Of AV-380 And Related Antibodies

AVEO Oncology (NASDAQ:AVEO) today announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO's first-in-class, potent, humanized inhibitory antibody targeting growth...

AVEO Oncology Reports Second Quarter 2015 Financial Results

AVEO Oncology Reports Second Quarter 2015 Financial Results

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2015.

AVEO Oncology To Host Midyear Update Conference Call On August 10, 2015

AVEO Oncology To Host Midyear Update Conference Call On August 10, 2015

AVEO Oncology (NASDAQ:AVEO) today announced that management will host a conference call on Monday, August 10, 2015, at 10:00 a.

AVEO Oncology Announces Exclusive Licensing Agreement With Pharmstandard For Tivozanib In Russia, Ukraine And CIS

AVEO Oncology Announces Exclusive Licensing Agreement With Pharmstandard For Tivozanib In Russia, Ukraine And CIS

AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into an exclusive license agreement with a subsidiary of Pharmstandard Group, the largest Russian pharmaceutical group ("Pharmstandard"), for the development,...

Interesting AVEO Call Options For September 18th

Interesting AVEO Call Options For September 18th

Investors in AVEO Pharmaceuticals, Inc. saw new options begin trading this week, for the September 18th expiration.

Exelixis Scores Much-Needed Kidney Cancer Study Win to Boost Drug Sales

Exelixis Scores Much-Needed Kidney Cancer Study Win to Boost Drug Sales

Exelixis plans to seek expanded approval for Cometriq to treat kidney cancer in early 2016.

AVEO Oncology Announces Additional Biomarker Analyses From BATON-CRC Tivozanib Study To Be Presented At The ESMO 17th World Congress On Gastrointestinal Cancer

AVEO Oncology Announces Additional Biomarker Analyses From BATON-CRC Tivozanib Study To Be Presented At The ESMO 17th World Congress On Gastrointestinal Cancer

AVEO Oncology (NASDAQ:AVEO) today announced that additional biomarker analyses from the BATON- ( Biomarker Assessment of Tivozanib in ONcology) CRC study will be presented at the European Society for Medical Oncology...

Today's Dead Cat Bounce Stock Is AVEO Pharmaceuticals (AVEO)

Today's Dead Cat Bounce Stock Is AVEO Pharmaceuticals (AVEO)

Trade-Ideas LLC identified AVEO Pharmaceuticals (AVEO) as a "dead cat bounce" (down big yesterday but up big today) candidate

AVEO Announces FDA Update For Tivozanib In Colorectal Cancer

AVEO Announces FDA Update For Tivozanib In Colorectal Cancer

AVEO Oncology (NASDAQ:AVEO) today announced that it has received written feedback from the U.

Playing Biotechs with the House's Money

Playing Biotechs with the House's Money

Here's how to lock in gains on risky small-cap biotechnology stocks.

AVEO Pharmaceuticals (AVEO) In A Perilous Reversal

AVEO Pharmaceuticals (AVEO) In A Perilous Reversal

Trade-Ideas LLC identified AVEO Pharmaceuticals (AVEO) as a "perilous reversal" (up big yesterday but down big today) candidate

AVEO Announces Receipt Of European Regulatory Guidance Regarding Potential Marketing Authorization Application For Tivozanib

AVEO Announces Receipt Of European Regulatory Guidance Regarding Potential Marketing Authorization Application For Tivozanib

AVEO Oncology (NASDAQ:AVEO) today announced that, following pre-submission advisory meetings to discuss the potential submission of a Marketing Authorization Application (MAA) for tivozanib in Europe for the treatment of...

AVEO Pharmaceuticals (AVEO) Is Today's Dead Cat Bounce Stock

AVEO Pharmaceuticals (AVEO) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified AVEO Pharmaceuticals (AVEO) as a "dead cat bounce" (down big yesterday but up big today) candidate

AVEO Oncology To Present At Jefferies 2015 Global Healthcare Conference

AVEO Oncology To Present At Jefferies 2015 Global Healthcare Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the Jefferies 2015 Global Healthcare Conference on Thursday, June 4, 2015 at 8:00 AM (ET) in New...

AVEO Oncology Announces New Corporate Headquarters In Cambridge, Massachusetts

AVEO Oncology Announces New Corporate Headquarters In Cambridge, Massachusetts

AVEO Oncology (NASDAQ:AVEO) today announced the relocation of its corporate headquarters to One Broadway in Cambridge, Massachusetts, effective today.

Perilous Reversal Stock: AVEO Pharmaceuticals (AVEO)

Perilous Reversal Stock: AVEO Pharmaceuticals (AVEO)

Trade-Ideas LLC identified AVEO Pharmaceuticals (AVEO) as a "perilous reversal" (up big yesterday but down big today) candidate

AVEO Pharmaceuticals (AVEO) Strong On High Relative Volume Today

AVEO Pharmaceuticals (AVEO) Strong On High Relative Volume Today

Trade-Ideas LLC identified AVEO Pharmaceuticals (AVEO) as a strong on high relative volume candidate

AVEO Oncology Announces Presentation Of Final Results Of Extension Study 902 And FDA Regulatory Feedback For Advancing Tivozanib In Renal Cell Carcinoma

AVEO Oncology Announces Presentation Of Final Results Of Extension Study 902 And FDA Regulatory Feedback For Advancing Tivozanib In Renal Cell Carcinoma

AVEO Oncology (NASDAQ:AVEO) announced today that final results from the TIVO-1 extension study, known as Study 902, in which patients with advanced renal cell carcinoma (RCC) received tivozanib as second-line treatment...

AVEO Oncology Reports First Quarter 2015 Financial Results

AVEO Oncology Reports First Quarter 2015 Financial Results

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2015.

Keith Ehrlich, Chief Financial Officer, AVEO Oncology

Keith Ehrlich, Chief Financial Officer, AVEO Oncology

AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Keith S.

TheStreet Quant Rating: D- (Sell)